Pilot trial of cisplatin, radiation, and WR2721 in carcinoma of the uterine cervix: A New York gynecologic oncology group study

Scott Wadler, Jonathan J. Beitler, John S. Rubin, Hilda Haynes-Lewis, Frances McGill, Alla Rozenblit, Gary Goldberg, Carmel Cohen, James Speyer, Carolyn Runowicz

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Purpose: A phase I trial of WR2721 was initiated to determine the maximal safe dose for incorporation into a consecutive 5-day schedule of cisplatin administered concurrently with radiation therapy in patients with cervical cancer. Patients and Methods: WR2721 was administered at 340 to 910 mg/m2/d immediately before cisplatin. Cisplatin was administered at 20 mg/m2/d for 5 days every 3 weeks in combination with external-beam radiation therapy and at 100 mg/m2 after each brachytherapy treatment. Pelvic radiation consisted of external-beam therapy to a dose of 39.6 Gy, followed by brachytherapy with cesium 137 tandem and ovoid insertions to deliver 80 Gy to point A and 55 Gy to point B. Results: Twenty patients were enrolled; 19 were as-sessable. The dose-limiting toxicity of WR2721 was hypotension. No patients developed serious sequelae, but hypotension required a reduction in the dose of WR2721 at the highest dose level tested. The major grade 3 or 4 toxicities included transient azotemia (five of 19), leukopenia (nine of 19), vomiting (four of 19), and neurotoxicity (two of 19). One patient experienced an anaphylactic reaction to cisplatin. Conclusion: The recommended dose of WR2721 administered in conjunction with cisplatin on a daily × 5 schedule plus radiation therapy is 825 mg/m2/d for 5 days.

Original languageEnglish (US)
Pages (from-to)1511-1516
Number of pages6
JournalJournal of Clinical Oncology
Volume11
Issue number8
StatePublished - 1993

Fingerprint

Cervix Uteri
Cisplatin
Radiation
Carcinoma
Radiotherapy
Brachytherapy
Hypotension
Appointments and Schedules
Azotemia
Cesium
Leukopenia
Anaphylaxis
Uterine Cervical Neoplasms
Vomiting
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pilot trial of cisplatin, radiation, and WR2721 in carcinoma of the uterine cervix : A New York gynecologic oncology group study. / Wadler, Scott; Beitler, Jonathan J.; Rubin, John S.; Haynes-Lewis, Hilda; McGill, Frances; Rozenblit, Alla; Goldberg, Gary; Cohen, Carmel; Speyer, James; Runowicz, Carolyn.

In: Journal of Clinical Oncology, Vol. 11, No. 8, 1993, p. 1511-1516.

Research output: Contribution to journalArticle

Wadler, S, Beitler, JJ, Rubin, JS, Haynes-Lewis, H, McGill, F, Rozenblit, A, Goldberg, G, Cohen, C, Speyer, J & Runowicz, C 1993, 'Pilot trial of cisplatin, radiation, and WR2721 in carcinoma of the uterine cervix: A New York gynecologic oncology group study', Journal of Clinical Oncology, vol. 11, no. 8, pp. 1511-1516.
Wadler, Scott ; Beitler, Jonathan J. ; Rubin, John S. ; Haynes-Lewis, Hilda ; McGill, Frances ; Rozenblit, Alla ; Goldberg, Gary ; Cohen, Carmel ; Speyer, James ; Runowicz, Carolyn. / Pilot trial of cisplatin, radiation, and WR2721 in carcinoma of the uterine cervix : A New York gynecologic oncology group study. In: Journal of Clinical Oncology. 1993 ; Vol. 11, No. 8. pp. 1511-1516.
@article{a198293ae86a4723a0ee696f36d723c8,
title = "Pilot trial of cisplatin, radiation, and WR2721 in carcinoma of the uterine cervix: A New York gynecologic oncology group study",
abstract = "Purpose: A phase I trial of WR2721 was initiated to determine the maximal safe dose for incorporation into a consecutive 5-day schedule of cisplatin administered concurrently with radiation therapy in patients with cervical cancer. Patients and Methods: WR2721 was administered at 340 to 910 mg/m2/d immediately before cisplatin. Cisplatin was administered at 20 mg/m2/d for 5 days every 3 weeks in combination with external-beam radiation therapy and at 100 mg/m2 after each brachytherapy treatment. Pelvic radiation consisted of external-beam therapy to a dose of 39.6 Gy, followed by brachytherapy with cesium 137 tandem and ovoid insertions to deliver 80 Gy to point A and 55 Gy to point B. Results: Twenty patients were enrolled; 19 were as-sessable. The dose-limiting toxicity of WR2721 was hypotension. No patients developed serious sequelae, but hypotension required a reduction in the dose of WR2721 at the highest dose level tested. The major grade 3 or 4 toxicities included transient azotemia (five of 19), leukopenia (nine of 19), vomiting (four of 19), and neurotoxicity (two of 19). One patient experienced an anaphylactic reaction to cisplatin. Conclusion: The recommended dose of WR2721 administered in conjunction with cisplatin on a daily × 5 schedule plus radiation therapy is 825 mg/m2/d for 5 days.",
author = "Scott Wadler and Beitler, {Jonathan J.} and Rubin, {John S.} and Hilda Haynes-Lewis and Frances McGill and Alla Rozenblit and Gary Goldberg and Carmel Cohen and James Speyer and Carolyn Runowicz",
year = "1993",
language = "English (US)",
volume = "11",
pages = "1511--1516",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

TY - JOUR

T1 - Pilot trial of cisplatin, radiation, and WR2721 in carcinoma of the uterine cervix

T2 - A New York gynecologic oncology group study

AU - Wadler, Scott

AU - Beitler, Jonathan J.

AU - Rubin, John S.

AU - Haynes-Lewis, Hilda

AU - McGill, Frances

AU - Rozenblit, Alla

AU - Goldberg, Gary

AU - Cohen, Carmel

AU - Speyer, James

AU - Runowicz, Carolyn

PY - 1993

Y1 - 1993

N2 - Purpose: A phase I trial of WR2721 was initiated to determine the maximal safe dose for incorporation into a consecutive 5-day schedule of cisplatin administered concurrently with radiation therapy in patients with cervical cancer. Patients and Methods: WR2721 was administered at 340 to 910 mg/m2/d immediately before cisplatin. Cisplatin was administered at 20 mg/m2/d for 5 days every 3 weeks in combination with external-beam radiation therapy and at 100 mg/m2 after each brachytherapy treatment. Pelvic radiation consisted of external-beam therapy to a dose of 39.6 Gy, followed by brachytherapy with cesium 137 tandem and ovoid insertions to deliver 80 Gy to point A and 55 Gy to point B. Results: Twenty patients were enrolled; 19 were as-sessable. The dose-limiting toxicity of WR2721 was hypotension. No patients developed serious sequelae, but hypotension required a reduction in the dose of WR2721 at the highest dose level tested. The major grade 3 or 4 toxicities included transient azotemia (five of 19), leukopenia (nine of 19), vomiting (four of 19), and neurotoxicity (two of 19). One patient experienced an anaphylactic reaction to cisplatin. Conclusion: The recommended dose of WR2721 administered in conjunction with cisplatin on a daily × 5 schedule plus radiation therapy is 825 mg/m2/d for 5 days.

AB - Purpose: A phase I trial of WR2721 was initiated to determine the maximal safe dose for incorporation into a consecutive 5-day schedule of cisplatin administered concurrently with radiation therapy in patients with cervical cancer. Patients and Methods: WR2721 was administered at 340 to 910 mg/m2/d immediately before cisplatin. Cisplatin was administered at 20 mg/m2/d for 5 days every 3 weeks in combination with external-beam radiation therapy and at 100 mg/m2 after each brachytherapy treatment. Pelvic radiation consisted of external-beam therapy to a dose of 39.6 Gy, followed by brachytherapy with cesium 137 tandem and ovoid insertions to deliver 80 Gy to point A and 55 Gy to point B. Results: Twenty patients were enrolled; 19 were as-sessable. The dose-limiting toxicity of WR2721 was hypotension. No patients developed serious sequelae, but hypotension required a reduction in the dose of WR2721 at the highest dose level tested. The major grade 3 or 4 toxicities included transient azotemia (five of 19), leukopenia (nine of 19), vomiting (four of 19), and neurotoxicity (two of 19). One patient experienced an anaphylactic reaction to cisplatin. Conclusion: The recommended dose of WR2721 administered in conjunction with cisplatin on a daily × 5 schedule plus radiation therapy is 825 mg/m2/d for 5 days.

UR - http://www.scopus.com/inward/record.url?scp=0027169249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027169249&partnerID=8YFLogxK

M3 - Article

C2 - 8393096

AN - SCOPUS:0027169249

VL - 11

SP - 1511

EP - 1516

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -